Non-alcoholic steatohepatitis: an overview (Q37381178)

20 August 2017

1 reference

title

Non-alcoholic steatohepatitis: an overview (English)

1 reference

non-alcoholic steatohepatitis

20 August 2017

0 references

1 reference

Allison Shifflet

1

1 reference

PubMed ID

19181602

20 August 2017

George Y Wu

series ordinal

2

1 reference

20 August 2017

1 January 2009

1 reference

Journal of the Formosan Medical Association

20 August 2017

1 reference

20 August 2017

108

1 reference

20 August 2017

1

1 reference

20 August 2017

4-12

1 reference

Defining nonalcoholic fatty liver disease: implications for epidemiologic studies

20 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Fatty liver and the metabolic syndrome among Shanghai adults

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Nonalcoholic steatohepatitis: An expanded clinical entity

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Nonalcoholic fatty liver disease: a feature of the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Comparison of the natural history of alcoholic and nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Non-alcoholic steatohepatitis: definitions and pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Pathogenesis of non-alcoholic steatohepatitis: human data

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Adiponectin and protection against type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Adiponectin and leptin in relation to insulin sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Adiponectin and its receptors in non-alcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Liver fibrogenesis: a new role for the renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl4 in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Alcoholic liver disease: new insights into mechanisms and preventative strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Insulin in UW solution exacerbates hepatic ischemia / reperfusion injury by energy depletion through the IRS-2 / SREBP-1c pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Iron-induced mitochondrial permeability transition in cultured hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Serum ferritin as a component of the insulin resistance syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Histological resolution of steatohepatitis after iron depletion

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Influence of liver biopsy heterogeneity and diagnosis of nonalcoholic steatohepatitis in subjects undergoing gastric bypass

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Quantitative evaluation of fatty liver by computed tomography in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Computed Tomography Features of Nonalcoholic Steatohepatitis With Histopathologic Correlation

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

The utility of radiological imaging in nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Out of phase magnetic resonance imaging and liver applications

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

The serum endothelin-1 level in steatosis and NASH, and its relation with severity of liver fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Effect of weight reduction on hepatic abnormalities in overweight patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Therapeutic effects of restricted diet and exercise in obese patients with fatty liver.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Fatty liver--an additional and treatable feature of the insulin resistance syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Hepatic dysfunction associated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Metformin in the treatment of patients with non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Laparoscopic adjustable gastric banding in the treatment of obesity: a systematic literature review

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Bariatric surgery: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Meta-analysis: surgical treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960026-7

7 January 2021

10.1016/S0929-6646(09)60026-7

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19181602